ALK-Abelló B A/S
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About ALK-Abelló B A/S
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.
/ 
Others were interested in
See all stocksFrequently asked questions
To buy ALK-Abelló B A/S stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for ALK-Abelló B A/S by name or ticker, choose the number of shares, and place your order.
The ticker symbol for ALK-Abelló B A/S is ALKb:xcse. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
ALK-Abelló B A/S has its primary listing on NASDAQ OMX Copenhagen. You can trade ALK-Abelló B A/S with a Saxo account, alongside thousands of other stocks worldwide.
Yes, ALK-Abelló B A/S is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include ALK-Abelló B A/S as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like ALK-Abelló B A/S.